The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach by Consolini, Rita et al.
August 2017 | Volume 5 | Article 1791
Review
published: 21 August 2017
doi: 10.3389/fped.2017.00179
Frontiers in Pediatrics | www.frontiersin.org
Edited by: 
Claudio Pignata, 
University of Naples 
Federico II, Italy
Reviewed by: 
Jenny McDade Despotovic, 
Baylor College of Medicine, 
United States  
Martina Pigazzi, 
University of Padua, Italy
*Correspondence:
Giorgio Costagliola 
giorgio.costagliola@hotmail.com
Specialty section: 
This article was submitted to 
Pediatric Immunology, 
a section of the journal 
Frontiers in Pediatrics
Received: 05 May 2017
Accepted: 07 August 2017
Published: 21 August 2017
Citation: 
Consolini R, Costagliola G and 
Spatafora D (2017) The Centenary of 
Immune Thrombocytopenia—Part 2: 
Revising Diagnostic and 
Therapeutic Approach. 
Front. Pediatr. 5:179. 
doi: 10.3389/fped.2017.00179
The Centenary of immune 
Thrombocytopenia—Part 2:  
Revising Diagnostic and  
Therapeutic Approach
Rita Consolini1, Giorgio Costagliola1* and Davide Spatafora2
1 Laboratory of Immunology, Department of Clinical and Experimental Medicine, Division of Pediatrics, University of Pisa, 
Pisa, Italy, 2 Clinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, 
Pisa, Italy
Primary immune thrombocytopenia (ITP) is the most common cause of thrombocytopenia 
in children and adolescents and can be considered as a paradigmatic model of autoim-
mune disease. This second part of our review describes the clinical presentation of ITP, 
the diagnostic approach and overviews the current therapeutic strategies. Interestingly, 
it suggests an algorithm useful for differential diagnosis, a crucial process to exclude 
secondary forms of immune thrombocytopenia (IT) and non-immune thrombocytopenia 
(non-IT), which require a different therapeutic management. Advances in understanding 
the pathogenesis led to new therapeutic targets, as thrombopoietin receptor agonists, 
whose role in treatment of ITP will be discussed in this work.
Keywords: immune thrombocytopenia, differential diagnosis, diagnostic algorithm, chronic thrombocytopenia, 
conventional therapy, new therapeutic targets
iNTRODUCTiON
The platelet threshold necessary to make diagnosis of thrombocytopenia has changed during years 
(1), and for immune thrombocytopenia (ITP) working group thrombocytopenia is defined as a 
condition characterized by a platelet count lower than 100,000 platelets per microliter (2).
Primary ITP is the most common cause of thrombocytopenia, having an estimated incidence of 
4–9 cases out of 100,000 people per year (3–6), with about half of the pediatric cases occurring in 
previously healthy children.
The first part of this review described the pathogenesis of the disease, with special attention to 
the role of innate immune system and impairment in megakaryopoiesis (7). In this second part, we 
focus on the clinical aspects of ITP, particularly on the differential diagnosis and new target therapies. 
The process of differential diagnosis has the aim to distinguish ITP from secondary IT (caused 
by infections, immune defects, and other pathologies) and non-IT, particularly inherited diseases, 
because all these conditions require different treatments.
Therapy of ITP was historically based on the progressive use of immunoglobulins, corticosteroids, 
and immunosuppressive agents: following the recent advances in the study of the pathogenesis of the 
disease, new therapeutic targets have been identified, potentially leading to innovative therapeutic 
strategies.
2Consolini et al. Revising Diagnosis and Therapy of ITP
Frontiers in Pediatrics | www.frontiersin.org August 2017 | Volume 5 | Article 179
CLASSiFiCATiON
Immune thrombocytopenia can be classified according to etiol-
ogy, disease evolution and age of onset. Etiologic classification 
will be discussed separately, to introduce the more common 
forms of secondary IT.
According to disease evolution, it is possible to identify three 
categories of ITP: newly diagnosed ITP; persistent ITP, still pre-
sent after 3 months from diagnosis; and chronic ITP, lasting 12 
or more months after diagnosis (2), which represents about 20% 
of the total cases of ITP in childhood (8).
IT affecting young children is typically acute and self-remitting, 
and primary forms are the most common in this age. Adolescents 
IT has an intermediate phenotype between childhood-onset and 
adult-onset forms (9), showing a higher rate of chronicity and a 
greater percentage of secondary IT.
eTiOLOGY OF iTP
Etiologic classification divides two categories of ITP: primary ITP 
and secondary IT.
The primary form of IT, classically defined “idiopathic,” is 
often seen in childhood and triggered by non-specific viral infec-
tions (upper respiratory or gastrointestinal infections): in some 
cases acute infections by Epstein–Barr virus, cytomegalovirus, 
parvovirus, rubella, mumps, and varicella have been identified as 
triggers of ITP (10–12).
Secondary IT has a complex etiology, as specific infections, 
drugs or vaccinations and immunologic abnormalities, including 
immunodeficiencies, can be involved in its pathogenesis.
infections
Infectious diseases caused by HIV, HCV, Helicobacter pylori, 
and dengue virus can be responsible of secondary IT, usually 
with chronic course (13–17), trough different mechanisms, like 
molecular mimicry, modulation of the immune system’s activity 
or suppression of bone marrow production (18). Association 
between pulmonary and extra-pulmonary TBC and IT is docu-
mented in only a few case reports (19, 20).
Drugs
Secondary IT can be caused by the assumption of drugs and 
vaccines: drug-induced IT, ascribable in most of cases to the 
assumption of certain antibiotics, non-steroidal anti-inflamma-
tory drugs, and antivirals, it is often not recognized, resulting 
in recurrent non-explained episodes of thrombocytopenia (21), 
that usually show a complete recovery after the withdrawal of the 
drug. Less commonly than in adulthood, it is possible to observe 
in childhood the development of heparin-induced thrombocy-
topenia (22).
Patients who received multiple transfusions are at risk for the 
development of posttransfusion purpura (PTP), a rare form of 
secondary IT with a high rate of bleeding: this is more frequent 
in multiparous female (18), but rare reports of PTP with pediatric 
onset are described (23).
immunodeficiency
Immune thrombocytopenia is a possible manifestation of immu-
nodeficiency, particularly common variable immunodeficiency 
(CVID), selective IgA deficiency, and DiGeorge’s syndrome. 
Is interesting to underline that, in humoral immune defects, the 
reduction of platelet count may appear years before the hypogam-
maglobulinemia (24–26).
Autoimmune Diseases
Systemic autoimmune diseases, such as systemic lupus erythe-
matosus (SLE), Sjogren’s syndrome, and antiphospholipid syn-
drome, are associated with the development of IT (27): an isolated 
thrombocytopenia may represent the initial manifestation of SLE, 
preceding the diagnosis by several years (28, 29).
Current literature reports an association between IT and clini-
cal and subclinical thyroid autoimmune diseases (Hashimoto’s 
and Basedow–Graves’ diseases), suggesting the presence of an 
overlap in the pathogenesis of these conditions (30, 31).
Moreover, many lymphoproliferative disorders may cause 
secondary ITP: in this category, the most frequent disease is 
autoimmune lymphoproliferative syndrome (32), mostly found 
in children aged under 3 years.
Neoplasia
Lymphatic malignancies, particularly non-Hodgkin’s lymphoma, 
represent a cause of IT (33), which rarely can be a paraneoplastic 
manifestation of a solid neoplasia (34, 35), mostly in adults.
Age-Related Considerations
In neonatal age, the most frequent form of IT is the alloimmune 
(36), caused by the production of maternal antibodies directed 
against platelet alloantigens.
In adolescent females, the possibility of an IT secondary to 
pregnancy should be considered (37).
OTHeR CAUSeS OF THROMBOCYTOPeNiA 
iN PeDiATRiC AGe
Other forms of thrombocytopenia occurring during childhood 
and adolescence could mime ITP and secondary IT, particu-
larly when platelet reduction is the only laboratory finding. 
Inherited thrombocytopenias, often misdiagnosed as ITP (38), 
are characterized by impairment in magakaryopoiesis and 
include a large variety of X-linked and autosomal diseases, 
commonly presenting with altered platelet size (39). Among 
them, Wiskott–Aldrich syndrome, caused by the mutation of 
WAS gene on chromosome X, usually comprehends the asso-
ciation of thrombocytopenia with small platelets, eczema, and 
immunodeficiency (40).
Thrombocytopenia occurs also in acute leukemia and primary 
bone marrow failure syndromes as Fanconi anemia, but in these 
cases, the association with other cytopenias helps making dif-
ferential diagnosis (41).
Also lisosomial storage disorders, as Gaucher’s and Niemann–
Pick’s disease, may present thrombocytopenia at clinical onset, 
usually accompanied by a considerable splenomegaly (42, 43).
TABLe 1 | Etiology of secondary IT and non-IT in childhood and adolescence.
Secondary iT Non-iT
•	 Immunodeficiencies: CVID, IgA 
deficiency, DiGeorge’s syndrome
•	 Infections: HIV, HCV, CMV, EBV, 
Helicobacter pylori, and TBC
•	 Drugs: NSAIDS, antibiotics, and 
antivirals
•	 Vaccines: influenza, poliomyelitis, 
pneumococcal, MMR, HPV, and 
HBV (44)
•	 Posttransfusion purpura
•	 Connective tissue disease: LES, 
Sjogren, and APLS
•	 Autoimmune thyroiditis: Basedow’s 
and Hashimoto’s diseases
•	 Lymphoproliferative disorders: ALPS
•	 Neoplasia: LNH and solid tumors 
(paraneoplastic)
•	 Alloimmune (neonatal)
•	 Pregnancy-associated IT
•	 Inherited disorders: autosomal 
dominant, autosomal recessive, and 
X-linked diseases
•	 Lisosomial storage disorders: 
Gaucher’s and Niemann–Pick’s 
disease
•	 Solid tumors with bone marrow 
infiltration (as neuroblastoma) (45)
•	 Hypersplenism and splenic 
sequestration
•	 Inherited and acquired bone marrow 
failure syndromes (MDS, AAA) (46)
•	 Acute leukemia
•	 Chemotherapy with bone marrow 
suppression (47)
•	 Disseminated intravascular 
coagulation (48)
•	 Thrombotic microangiopathy (HUS/
TTP) (49)
•	 Kasabach–Merritt Syndrome (50)
CVID, common variable immunodeficiency; MMR, measles, mumps, and rubella; 
ALPS, autoimmune lymphoproliferative syndrome; MDS, myelodisplastic syndrome; 
AAA, acquired aplastic anemia; HUS: hemolytic–uremic syndrome; TTP, thrombotic 
thrombocytopenic purpura; CMV, cytomegalovirus; EBV, Epstein–Barr virus; NSAIDS, 
non-steroidal anti-inflammatory drugs; IT, immune thrombocytopenia.
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Other less common conditions are indicated in Table 1, which 
summarizes the most relevant causes of secondary IT and non-IT 
in childhood and adolescence.
CLiNiCAL PReSeNTATiON
Immune thrombocytopenia is not rarely asymptomatic, being 
observed during routinely laboratory evaluations. In symptomatic 
cases, the most common presenting feature is epistaxis (51), fol-
lowed by cutaneous and mucosal minor bleeding.
Severe bleeding rates are more common in childhood 
compared to adult patients: a review by Neunert et  al. showed 
that severe bleeding occurs in 20.2% of children and 9.6% of 
adults (52).
The most severe bleeding event is ITP-associated intracranial 
hemorrhage (ICH): it represents a rare cause of pediatric stroke 
(53), affecting only 0.4% of children with ITP (52), but com-
plicated by elevated mortality rates, reported between 12 and 
25% in recent studies (54–58). ICH, as other severe bleedings, 
occurs mostly in children with other features of bleeding and 
in patients with a platelet count lower than 10,000/μl (59) and 
is often preceded by a precipitant factor, like head trauma (55, 
60, 61).
An anamnesis positive for previous minor bleeding is a risk 
factor for severe haemorrhagic events (52), while the clinical 
relevance of an occult hemorrhage, often identified in urinary 
tract, is not completely defined, as studies reported different 
conclusions about the association with future overt bleeding and 
ICH (55, 62).
DiAGNOSiS
Diagnosis of ITP remains one of exclusion, and differential 
diagnosis with secondary forms is crucial, because in these 
cases thrombocytopenia may be less responsive to conventional 
therapy, but only to the treatment of primary cause.
Interview should focus on the potential triggers of ITP (assump-
tion of drugs, vaccines, and transfusions) and risk factors for 
secondary forms, as the presence of weight loss, chronic infections 
(HIV and HCV) and other immune-mediated disease. It is also 
important to investigate elements suggestive of inherited throm-
bocytopenia, as previous bleedings and positive familiar history.
During physical assessment, the clinician must search poten-
tial sites of bleeding (cutaneous and mucosal) and identify signs 
suggestive for secondary IT or other pathologies, by examining 
the presence of hepatosplenomegaly, abdominal masses, lym-
phoadenopathies, and bone pain.
Furthermore, we analyze the diagnostic the most relevant 
laboratory investigations in ITP, to introduce our diagnostic 
algorithm.
LABORATORY iNveSTiGATiONS
Full Blood Count with Citrate and 
Reticulocyte Determination
First laboratory step, has the role of excluding a pseudothrom-
bocytopenia (EDTA related) (63) and the presence of other 
cytopenias. Patients with severe bleeding could show anemia, 
related to blood loss. In case of multiple cytopenias, diagnosis of 
ITP is unlikely and becomes mandatory to investigate for acute 
leukemia, lymphomas, bone marrow failure (aplastic anemia), 
and neoplastic infiltration of bone marrow.
Mean Platelet volume (MPv)
Mean platelet volume is useful in the first laboratory assessment 
and is normal or slightly high in patients with ITP, while it shows 
alterations (marco- or micro-thrombocythemia) in almost all 
patients with inherited thrombocytopenia. Due to the lack of 
validated thresholds, this exam is significant in presence of a great 
difference in MPV, as it happens in inherited thrombocytopenia, 
in which platelet volume can be 50–100% higher than normal 
values (64). In some particular cases, as mono- and biallelic 
Bernard–Soulier syndrome (65) and MYH-9-related disease, 
giant platelets may not be recognized by automatic counters, 
underestimating MPV and platelet count (66, 67).
Peripheral Blood Smear
It may demonstrate alterations on red blood cells (for example, 
schistocytes in HUS/TTP) and white cells (blasts in leukemia), 
which exclude diagnosis of ITP (68). Moreover, analysis of blood 
smear could be useful to identify alterations of platelet size and 
correct measurement of their diameters. Many of congenital 
thrombocytopenias have also changes in platelet morphology, 
recognizable with blood smear (69). The interpretation of blood 
smear requires experience, and access may be limited in resource 
poor regions, making it not always applicable as a first-line tool.
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Reticulated Platelet Count (RPLT)
First described in 1969 (70), reticulated platelets are immature 
platelets circulating in the blood, containing a residual RNA. 
They can be analyzed with flow cytometry and give an indirect 
determination of thrombopoietic rate (71). Lack of standardiza-
tion of methods and definition of threshold values make difficult 
the interpretation of RPLT value (72): even if the applicability 
of RPLT determination is not completely defined, recent works 
conclude that this is a promising tool to distinguish thrombocy-
topenia caused by bone marrow hypoproduction to that one due 
to platelet destruction (73). Moreover, a study by Thomas-Kaskel 
et  al. demonstrated the correlation between reticulated platelet 
count and response to treatment (74).
Rh (D) Typing
This exam should be performed in those patients candidate 
for receiving therapy with anti-D immunoglobulins (75–77). 
Currently, this treatment is no longer licensed in Europe (51), 
where Rh typing is not yet recommended.
Autoantibodies
Antiplatelet antibodies showed absence of specificity for ITP, 
and therefore the determination is not routinely recommended 
(78). Other autoantibodies, particularly antinuclear (ANA) and 
antithyroid antibodies, may have a diagnostic role in identify-
ing secondary IT or, respectively, patients at risk of developing 
chronic thrombocytopenia and thyroid diseases. Testing for these 
antibodies is particularly useful in patients with persistent or 
chronic ITP, as discussed in the Section “Prognosis and Sequelae.”
Bone Marrow examination
The analysis of bone marrow of a patient with ITP would show an 
increase in number of megakaryocytes and absence of alterations 
in other cellular lines. In patients with isolated thrombocytopenia, 
diagnosis of acute leukemia or lymphoma is unlikely, and bone 
marrow biopsy and aspirate are rarely useful. Several authors 
agree affirming that bone marrow biopsy and aspirate must be 
performed in children and adolescents with atypical findings for 
ITP (51, 79–81).
Moreover, bone marrow examination should be performed in 
patients with absence of response to standard treatments, before 
the beginning of second-line therapies and the execution of 
splenectomy (82).
ALGORiTHM FOR DiFFeReNTiAL 
DiAGNOSiS
The algorithm we suggest for differential diagnosis of new onset 
thrombocytopenia, shown in Figure 1, is composed by one clinical 
step and three laboratory and radiological steps and is primarily 
directed to patients without acute and severe bleeding. We focused 
particularly on the exclusion of short-term life-threatening con-
ditions, such as acute leukemia, lymphomas, and other neoplasia, 
while chronic infections and systemic autoimmune disease with 
partial expression are investigated in later steps. The algorithm is 
progressive, and therefore the investigations included in steps 3 
and 4 are usually indicated only in patients with persistent and 
chronic ITP.
The clinical step remains fundamental: in case of severe bleed-
ing signs, it is mandatory to treat the patient, and the required 
investigations are different (see Consideration on Patients with 
Acute Bleeding). Moreover, if anamnesis or physical assessment 
shows elements indicative for secondary IT (abdominal masses 
and adenopathies), the algorithm becomes not necessary, and the 
laboratory and radiological approach must start with investiga-
tions directed to confirm the etiologic hypothesis suggested by 
the clinical findings.
The second step comprehends laboratory exams directed to 
identify the conditions that more frequently cause secondary IT 
and non-ITP, including inherited thrombocytopenia, infections, 
immunodeficiency, and lymphoid malignancies.
The third step includes an abdominal echography, useful 
to recognize alterations in liver, spleen, and abdominal lymph 
nodes, not always appreciable during clinical examination. This 
step also considers the determination of reticulated platelet 
count: despite the lack of standardization of values and difficul-
ties in interpretations, this investigation, when available, can 
give important information about thrombopoietic rate, and thus 
remains an option to consider.
The last step comprehends investigations for autoimmune 
diseases and chronic infections. Determination of ANA is 
also important to predict the evolution to a chronic form (see 
Prognosis and Sequelae).
Consideration on Patients with Acute 
Bleeding
In this case, primary diagnostic approach should exclude con-
ditions, such as HUS/TTP, DIC, antiphospholipid syndrome, 
coagulation abnormalities, and neoplasia (promyelocytic leu-
kemia). First-step analyses include determination of full blood 
count, blood smear (if available), coagulation tests, APL, LDH, 
and D-dimer, accompanied by the evaluation of the bleeding site 
(echography, endoscopy, and neuroimaging). In case of negative 
results or resolution of the bleeding episode, it is possible to apply 
the diagnostic algorithm discussed above.
THeRAPY
About two out of three pediatric patients with ITP show a 
spontaneous improvement in platelet count in 6 months without 
necessity of medical treatment, and those remissions are usually 
sustained. Most of patients with newly diagnosed ITP do not 
show signs of bleeding, and can be managed with a “watch and 
see” strategy (83–86).
There is no absolute consensus about the platelet threshold 
necessary to start treatment in ITP: 1996 guidelines of the 
American Society of Hematology recommended to treat patients 
with a platelet count lower than 10,000/μl and minor purpura 
or those one with a count lower 20,000/μl and significant bleed-
ing (87). An update published in 2011 suggested that children 
without bleeding or with mild bleeding should be managed only 
with observations, regardless of platelet count (88). Despite these 
FiGURe 1 | Algorithm for differential diagnosis of immune thrombocytopenia, composed by four progressive steps. *Testing for Epstein–Barr virus (EBV), 
cytomegalovirus (CMV), and HCV is recommended if not done in previous step. **Helycobacter pylori testing should be performed in high prevalence area or 
clinical suspect.
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recommendations, most patients with low risk of bleeding are 
currently treated (89).
First-line Treatment
Prednisone–Prednisolone
All guidelines support the use of corticosteroids in the first-
line treatment of ITP. Oral prednisone is often effective in 
inducing response in pediatric patients when administered at 
doses of 1–2 mg/kg for 7–14 days and maintains efficacy also 
at higher doses (4 mg/kg/day) for 3 or 4 days, raising platelet 
count over 50,000/μl in the first 72  h in 72–88% of patients 
(78, 90, 91).
However, due to the adverse effects of a prolonged treat-
ment with corticosteroids in children, those drugs must be 
used only for short periods, to maintain a hemostatic platelet 
count (78).
Intravenous Immunoglobulins (IVIg)
Immunoglobulins have been used for ITP since 1981 (92, 93), 
for the effect of modulation on immune system. The treatment 
induces a raise in platelet count in 80% of pediatric patients, 
obtaining an effect in the first 48  h more frequent than corti-
costeroids (94). IVIg are usually administered in a single dose 
of 0.8–1  g/kg, with the chance of using a second dose in case 
6Consolini et al. Revising Diagnosis and Therapy of ITP
Frontiers in Pediatrics | www.frontiersin.org August 2017 | Volume 5 | Article 179
of incomplete response, even if also lower doses (0.6 g/kg) are 
reported to be effective (95). Adverse effects include headache 
and fever and are more common when used doses are greater 
than 1 g/kg for consecutive days (91).
Intravenous Anti-D Immunoglobulin
Rh-positive children could receive short infusions of anti-D 
immunoglobulin, with a recommended dose of 50–75 µg/kg (78). 
This therapeutic strategy has a response rate greater than 50% and 
acts more rapidly than IVIG (76, 77, 96, 97).
However, in patients with comorbidity, the treatment has 
been associated with severe hemolysis, acute renal failure, and 
disseminated intravascular coagulation, and therefore anti-D 
immunoglobulin administration should require a careful selec-
tion of patients and post-therapy monitoring, as concluded by 
Despotovic et al. (98).
Second-line Therapies
High-Dose Corticosteroids
High-dose methylprednisolone has been used as an alternative to 
IVIg, showing comparable response rates (99, 100).
Dexamethasone (28–40 mg/m2/day) has been used in pediat-
ric patients with chronic refractory ITP, obtaining response rates 
greater than 80%, with and a mean duration of the response of 
26 months (101): moreover, psychiatric adverse effects, such as 
insomnia and aggressive behavior, are extremely frequent (102), 
and this makes dexamethasone only a second-line therapeutic 
alternative.
Rituximab
This anti-CD20 antibody, used in other autoimmune diseases and 
B-cell lymphoma, has been used in chronic refractory ITP often 
showing response rates greater than 60% (103–106), even though 
in a study by Bennett et al. only 31% of patients responded (107). 
However, follow-up studies have shown that sustained response 
is uncommon (108, 109), and safety profile is unclear.
Danazol
This attenuated androgen is successfully used in second-line treat-
ment of adult patients with ITP, particularly in elderly patients 
(110). There are only a few studies about its use in pediatric 
patients, showing a good effectiveness without significant adverse 
reactions. Unfortunately, danazol can accelerate bone growth, 
and this limits its applicability in prepuberal patients (111, 112).
Thrombopoietin Receptor Agonists (TPO-RAs)
Since the discovery of the role of thrombopoietin (TPO) in ITP 
several thrombopoietic drugs was tested (113), and in 2008 FDA 
approved two TPO receptor agonists for non-responsive ITP in 
adults: romiplostim and eltrombopag (114, 115). Romiplostim 
acts on TPO-binding subunit of the receptor and is adminis-
tered subcutaneously weekly (116). It is not yet approved for 
childhood-onset ITP, although in several studies it showed a 
50–80% response rate, without severe adverse effects (117–125).
Eltrombopag acts binding the transmembrane domain of TPO 
receptor and is administered orally daily (116). It showed response 
rates greater than 60% in two randomized trials, associated with 
a good tolerability (126, 127), so in 2015 FDA has approved it 
for the use in childhood-onset disease. Reported adverse effects 
consist in an increased risk of hepatic damage and cataract.
Recently, avatrombopag, a new drug with an eltrombopag-like 
mechanism of action, was included in clinical trials for adults, 
showing response rate similar to other TPO-RAs in absence of 
severe adverse effects (128). In summary, TPO-RAs seem to be 
safe end effective also in childhood-onset refractory ITP.
Use of Immunosuppressors
There are only a few studies investigating the role of immuno-
suppressive agents, single or in combination, in patients with 
refractory ITP, and experience in childhood is not enough strong 
to give specific recommendations (78). Azathioprine, used in 
several autoimmune pediatric diseases, is still an option for the 
treatment of adult patients with ITP, particularly in chronic ITP 
and when splenectomy is contraindicated or has been ineffective 
(129). Response is detectable after about 4 months, and adverse 
effects, such as posttreatment leukemia, are extremely rare (130).
In pediatric age, cyclosporine is used in several conditions 
(organ transplants, autoimmune hepatitis, acquired aplastic ane-
mia, juvenile dermatomyositis, and nephrotic syndrome) while 
its applicability in ITP is not completely defined. In adult 
patients, this drug often shows positive response rates both in 
single therapy and in association with steroids, with possibility of 
sustained remission after discontinuation of treatment (131, 132). 
Despite the lack of evidence in childhood-onset ITP and the 
necessity of further studies, these data support the potential util-
ity of immunosuppressive agents as a second-line treatment in 
refractory ITP.
Splenectomy
Several studies reported a response in almost 85% of patients 
after splenectomy, with a 20–25% of relapses during the following 
years (133–135). Many works investigated the role of potential 
predictors of response to splenectomy in children and adults and 
suggested that female sex, younger age, response to steroids, and 
higher platelet count could be positive prognostic determinants, 
although the role of response to steroids is not univocally accepted 
(135–141).
Patients who received splenectomy are at risk of developing 
relevant adverse effects, particularly infections and sepsis by 
capsulated bacteria, with reported mortality rates of 3% (133), 
and thus the procedure is rarely recommended in children (78), 
being usually performed only in selected cases.
New Therapeutic Targets
There are ongoing trials about other classes of drugs for ITP, 
currently limited to application in adulthood. New potential 
targets are represented by interaction between T-cells and 
antigen-presenting cells (anti-CD40L antibodies) (142), platelet 
phagocytosis [SYK inhibitors and interference with FcR binding 
on macrophages (143)], activation of B-cells (anti-CD52 or alem-
tuzumab) (144) and T-cells [anti-IL-2R or daclizumab (145)], and 
TH1 expansion (anti-CD16) (146, 147). Figure  2 summarizes 
the new therapeutic targets for ITP and the corresponding drug 
classes.
FiGURe 2 | (Left) The new therapeutic targets identified by the study of pathogenesis of immune thrombocytopenia. (Right) Corresponding drug classes.
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emergency Treatment in Childhood
In both adult and childhood-onset disease, in cases of life- 
threatening hemorrhage or organ damage, it is necessary to obtain 
a rapid raise in platelet count, to reduce bleeding risk. Consensus 
document of 2010 recommends to administer a high dose of 
platelet (two to three times larger than usual), accompanied with 
intravenous corticosteroids and IVIg. In particular cases, such as 
unstoppable bleeding, it is possible to consider the execution of a 
splenectomy in emergency (78).
PROGNOSiS AND SeQUeLAe
Immune thrombocytopenia in childhood is usually self-remitting, 
while there is the possibility of reactivation of the disease follow-
ing viral infections or other triggers. The major sequelae of acute 
episodes are represented by permanent neurologic damages, 
defined as epilepsy, cognitive and learning disorder, and paresis, 
that can be detected in patients surviving the acute event of ICH 
(55, 148).
Adolescents are more likely to develop a chronic disease: 
a recent work by Heitink-Pollè et  al. identified some predic-
tors of chronic ITP, including female sex, age >11, insidious 
onset, absence of a trigger (infection or vaccination), and ANA 
positivity (149).
Patients with chronic ITP can undercover secondary 
misdiagnosed forms, as chronic infections, CVID, or other 
autoimmune pathologies, suggesting that this subset of patients 
need continuous reevaluation and discussion of primary diag-
nosis. Moreover, rarely, these patients may show an evolution 
to SLE: since there are no specific predictors of this progression 
(150), a study by Panzer et al. suggested that combined assess-
ment of ANA and anti-DsDNA may have a role in identifying 
subjects at higher risk (151), who need to be periodically 
monitored.
CONCLUSiON
The centenary of ITP traced history characterized of new progres-
sive knowledge, making it a paradigmatic model of autoimmune 
disease. In this issue, a second part of a revision of ITP story, 
we focused on ITP diagnostic approach. By combining physical 
examinations and laboratory findings, we designed a diagnostic 
algorithm, to dissect the complex diagnosis, substantially based 
on the exclusion of the multiple possible concurrent causes of 
thrombocytopenia. We described conventional therapy of ITP 
and focused on the new therapeutic targets.
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